首页-日语 - 地盘 - 记录 - 日志 - 下载 - 查词 - 翻译 - 排行
F8键(暂停/播放)| F9键(重复此句)| 左键或ALT+Z(上一句)| 右键或ALT+X(下一句)
听写窗口
译文窗口
注释窗口

您没有登录,系统不能保存您的听写记录和听写错词,点击此处登录

听写提交之后可查看原文
Convalescent plasma, which has long been used to treat diseases, has become the latest issue in the race to find treatment for COVID-19.
On Sunday, President Donald Trump announced that the United States would permit the emergency use of convalescent plasma to treat COVID-19 patients.
Trump called it "a breakthrough."
However, the World Health Organization on Monday warned that the treatment is still experimental.
The group described the evidence in support of the treatment as "low quality."
Trump made the plasma announcement after his administration accused the U.S. Food and Drug Administration of delaying in order to hurt his re-election chances this November.
The emergency approval makes it easier for some patients to get the treatment.
However, it is not the same as full FDA approval for treatment.
In its announcement, the FDA said,
"it is reasonable to believe that COVID-19 convalescent plasma may be effective in lessening the severity or shortening the length of COVID-19 illness in some hospitalized patients."
长期以来一直用于治疗各种疾病的康复者血浆成为寻找新冠肺炎疗法竞争中的最新焦点。
上周日,美国总统唐纳德・特朗普宣布美国将紧急授权使用康复者血浆治疗新冠肺炎患者。
特朗普称此举为“重大突破”。
然而,世界卫生组织(简称WHO)周一警告称,这种疗法仍处于试验阶段。
世卫组织称支持该疗法的证据“质量很低”。
特朗普宣布血浆疗法之前,其政府指责美国食品药品监督管理局(简称FDA)为损害其今年11月的连任机会而故意拖延。
紧急授权使一些患者更容易得到这种治疗。
然而,这不等同于美国食品药品监督管理局完全批准了这种疗法。
美国食品药品监督管理局在声明中表示,
“我们有理由相信,新冠肺炎康复者血浆可以有效减轻某些新冠肺炎住院患者的严重程度或缩短其病程。”
暂无注释
听写注意
1.为防止灌水听写至少要输入超过10个单词方可提交同时听写内容不能粘贴;
2.标点符号不用填写,听写比对会忽略掉标点符号;
3.单词与单词之间要留有空格,同时数字(年月或金额)请用阿拉伯数字。
可友留言
加载中...
我来说2句
抱歉,您需要先登录后才能留言
谁正在听写
得分最高
最新听写
热门听写